{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:14:17Z","timestamp":1779236057881,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2007,10]]},"abstract":"\n Objective:<\/jats:title>\n To report pharmacokinetic alterations and optimal dosing of piperacillin\/tazobactam in an obese patient.<\/jats:p>\n <\/jats:sec>\n \n Case Summary:<\/jats:title>\n \n A 39-year-old morbidly obese (weight 167 kg, body mass index 50 kg\/m\n 2<\/jats:sup>\n ) man was treated with piperacillin\/tazobactam 3.375 g every 4 hours for recurrent cellulitis. The wound culture grew Groups A and B Streptococcus and rare Pseudomonas aeruginosa. Blood samples were obtained at steady-state from a peripheral venous catheter at 0, 0.5, 1, 2, 3, and 4 hours after the start of the infusion. Population pharmacokinetics were generated from a previously published data set. The serum concentrations of piperacillin\/tazobactam obtained in the patient were compared with the 95% confidence interval from the representative population. Pharmacokinetic parameters such as maximal serum concentration, minimal serum concentration, average steady-state concentration, half-life, elimination rate constant, volume of distribution (V\n d<\/jats:sub>\n ), clearance, area under the curve at steady-state, and percent of time greater than the minimum inhibitory concentration (%t>MIC) were calculated and qualitatively compared between the sample and the population.\n <\/jats:p>\n <\/jats:sec>\n \n Discussion:<\/jats:title>\n \n Substantial differences were noted in both the absolute values at the times of sample collection and the overall concentration-versus-time profile of both compounds. The morbidly obese individual compared with the population demonstrated a reduced average serum steady-state concentration: 39.8 mg\/L versus 123.6 mg\/L, an increased V\n d<\/jats:sub>\n : 54.3 L versus 12.7 L, and an increased half-life: 1.4 hours versus 0.6 hours, respectively. The %t>MIC of piperacillin for the patient, assuming MICs of 2, 4, 8, 16, 32, 64, and 128 mg\/L, was 100%. 100%, 90.9%, 55.4%. 19.9%, 0%, and 0%, respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Pathogens with elevated MICs may require altered dosing schemes with piperacillin\/tazobactam. Future studies are warranted to assess increased dosages, more frequent dosing intervals, or continuous infusion dosing schemes for obese individuals with serious infections.<\/jats:p>\n <\/jats:sec>","DOI":"10.1345\/aph.1k256","type":"journal-article","created":{"date-parts":[[2007,8,28]],"date-time":"2007-08-28T22:34:03Z","timestamp":1188340443000},"page":"1734-1739","source":"Crossref","is-referenced-by-count":32,"title":["Serum Piperacillin\/Tazobactam Pharmacokinetics in a Morbidly Obese Individual"],"prefix":"10.1177","volume":"41","author":[{"given":"Diane","family":"Newman","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H","family":"Scheetz","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Midwestern University, Chicago; Infectious Diseases Pharmacist, Department of Pharmacy, Northwestern Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwadamilola A","family":"Adeyemi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, and Northwestern Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Montevecchi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Feinberg School of Medicine, Northwestern University, and Northwestern Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary A","family":"Noskin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, and Northwestern Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Postelnick","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2007,10,1]]},"reference":[{"key":"bibr1-aph.1K256","volume-title":"CLSI document M100-S16","author":"Clinical and Laboratory Standards Institute.","year":"2006"},{"key":"bibr2-aph.1K256","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki243"},{"key":"bibr3-aph.1K256","unstructured":"Part I. basic principles. In: WinterM, ed. Basic clinical pharmacokinetics. Baltimore: Lippincot, Williams and Wilkins, 2004."},{"key":"bibr4-aph.1K256","unstructured":"Product information. Zosyn (piperacillin and tazobactam). Philadelphia, PA: Wyeth Pharmaceuticals, Inc., October 2005."},{"key":"bibr5-aph.1K256","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050403"},{"key":"bibr6-aph.1K256","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"bibr7-aph.1K256","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200309-1256CC"},{"key":"bibr8-aph.1K256","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038050-00003"},{"key":"bibr9-aph.1K256","author":"Pai MP","year":"2007","journal-title":"Society of Infectious Diseases Pharmacists Newsletter"},{"key":"bibr10-aph.1K256","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-2059-6"},{"key":"bibr11-aph.1K256","unstructured":"Data on file (GTR-35385, 1999). Philadelphia, PA: Wyeth Pharmaceuticals, Inc."},{"key":"bibr12-aph.1K256","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.721"},{"key":"bibr13-aph.1K256","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf130"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1K256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1K256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:28Z","timestamp":1777374508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1K256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1345\/aph.1K256"],"URL":"https:\/\/doi.org\/10.1345\/aph.1k256","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}